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Abstract
Objective. To compare the efficacy and safety of mycophenolate mofetil (MMF) and intravenous cyclo-
phosphamide (IVC) as induction treatment for lupus nephritis (LN), by race, ethnicity and geographical
region.
Methods. A total of 370 patients with active Class III–V LN received MMF (target dose 3.0g/day) or IVC
(0.5–1.0g/m
2/month), plus tapered prednisone, for 24 weeks. Renal function, global disease activity,
immunological complement (C3 and C4) and anti-dsDNA levels are the outcomes that were assessed
in this study.
Results. MMF was not superior to IVC as induction treatment (primary objective). There were important
pre-specified interactions between treatment and race (P¼0.047) and treatment and region (P¼0.069)
(primary endpoint). MMF and IVC response rates were similar for Asians (53.2 vs 63.9%; P¼0.24) and
Whites (56.0 vs 54.2%; P¼0.83), but differed in the combined Other and Black group (60.4 vs 38.5%;
P¼0.03). Fewer patients in the Black (40 vs 53.9%; P¼0.39) and Hispanic (38.8 vs 60.9%; P¼0.011)
groups responded to IVC. Latin American patients had lower response to IVC (32 vs 60.7%; P¼0.003).
Baseline disease characteristics were not predictive of response. The incidence of adverse events (AEs)
was similar across groups. Serious AEs were slightly more prevalent among Asians.
Conclusions. MMF and IVC have similar efficacy overall to short-term induction therapy for LN. However,
race, ethnicity and geographical region may affect treatment response; more Black and Hispanic patients
responded to MMF than IVC. As these factors are inter-related, it is difficult to draw firm conclusions
about their importance.
Trial registration. National Institutes of Health, www.clinicaltrials.gov, registration number NCT00377637.
Key words: Cyclophosphamide, Lupus nephritis, Mycophenolate mofetil, Race, Randomized clinical trial.
Introduction
SLE is a genetically complex, highly heterogeneous,
autoimmune disease with an incidence, prevalence,
disease activity and prognosis that have been shown to
differ with race and ethnicity [1–6].
Up to 60% of patients with SLE develop lupus nephritis
(LN), a manifestation that is associated with a worse over-
all prognosis [7, 8]. As with SLE, there may also be racial,
ethnic or regional variations in the incidence, prevalence
and prognosis of LN. Studies have reported greater risks
of LN among African and Hispanic Americans compared
with European Americans [9, 10], with further observations
that Black and Hispanic patients with LN are more likely to
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disease and mortality compared with other racial/ethnic
groups [10–14].
One current debate is whether the treatment of severe
LN with intravenous cyclophosphamide (IVC) plus corti-
costeroids may be less effective in patients of African or
Hispanic descent [14–16]. Samples from previous trials
have been limited in the extent of geographical or racial
diversity and thus have not allowed rigorous com-
parisons by race/ethnicity and geographical area. The
Aspreva Lupus Management Study (ALMS), however,
offers a unique opportunity to compare different immuno-
suppressive treatments among different racial or ethnic
groups from distinct geographical locations. ALMS was
established to examine the efficacy and safety of
mycophenolate mofetil (MMF) compared with IVC when
administered with corticosteroids as induction therapy
for patients who were from a diverse range of racial and
ethnic groups and locations worldwide, with active Class
III–V LN [17, 18]. In the prospectively planned primary
efficacy analysis, statistically significant interactions
between treatment group and race or geographical
region were observed, suggesting that race and region
may play a role in response to therapy, as has been
suggested in smaller studies [14–16]. We, therefore,
undertook additional analyses of the efficacy and safety
data with respect to race, ethnicity and geographical
region.
Methods
Studydesign
ALMS [protocol WX17801, National Institutes of Health
(NIH) registration number NCT00377637; registered at
www.clinicaltrials.gov] was a prospective, randomized,
open-label, parallel-group, multicentre clinical trial.
Detailed methodology of the study has been published
elsewhere [17]. The study was conducted in accordance
with the Declaration of Helsinki and the principles of Good
Clinical Practice. The institutional review boards at all
participating centres approved the protocol and all
patients provided written, informed consent.
Patients
In brief, patients aged 12–75 years, who fulfilled ACR
criteria [19], with a diagnosis of SLE and histologically
confirmed LN (Classes III–V with active or active/chronic
lesions, International Society of Nephrology/Renal
Pathology Society classification [20]) were enrolled at
88 hospital clinics in 20 countries in Asia, Australia,
Europe, Latin America, USA and Canada between July
2005 and October 2006. The exclusion criteria have
previously been reported elsewhere [18].
Patients were categorized according to their self-
reported racial (Asian, Black, White and Other) and
ethnic (Hispanic or non-Hispanic) groups and according
to geographical region (Asia, Latin America, USA/Canada
and Rest of World).
Interventions
Patients underwent randomization (1:1, stratified by race
and biopsy class) to receive oral MMF twice a day, titrated
from 1g/day in Week 1 and 2g/day in Week 2 to a target
dose of 3g/day in Week 3, or IVC (monthly pulses of
0.5–1.0g/m
2) according to the modified NIH protocol
[21] for a total of 24 weeks (induction phase). If a patient
demonstrated consistent intolerance of MMF doses of
3g/day, but could tolerate 2–2.5g/day, or if the patient
weighed 450kg, the patient could remain in the study
at the dose of 2–2.5g/day. No therapeutic drug monitoring
was performed during the study, although pill counts were
monitored at every visit, and blood samples were taken at
random during the study for population pharmacokinetic
analysis.
A 25% reduction in IVC for patients aged >60 years or
a 25% reduction in serum creatinine level >300mol/l
(3.4mg/dl) was permitted. Temporary dose stoppage
of MMF or IVC was allowed for no more than 7 days in
total during the study. All patients received prednisone,
using a defined taper from a maximum starting dose
of 60mg/day. Prednisone dose was decreased by
10mg/day every 2 weeks until a dose of 40mg/day was
reached, and then by a further 5mg/day every 2 weeks
until a dose of 10mg/day was reached [17]. Dose reduc-
tion of <10mg/day was allowed after 4 weeks of stable
response [17]. The protocol was designed to standardize
the management of LN across all geographical regions.
Assessments
The primary efficacy parameter was the proportion of
patients responding to treatment at the end of the
24-week induction phase of the study. Response was
defined as a decrease in urine protein/creatinine ratio
(P/Cr), measured over 24h, to <3 in patients with baseline
nephrotic range P/Cr (53 at baseline), or by 550%
in patients with sub-nephrotic baseline P/Cr (<3) and
stabilization ( 25%) or improvement in serum creatinine
levels.
Secondary efficacy variables included the BILAG
index, the Safety of Exogenous Estrogens in Lupus
Erythematosus National Assessment–SLEDAI (SELENA–
SLEDAI) scale [22–24], the immunological complement
concentration (C3 and C4) and anti-dsDNA autoantibody
binding levels. Safety was assessed throughout the study
by monitoring adverse events (AEs), vital signs, and
clinical laboratory parameters, and performing physical
examinations.
Statistical analysis
The primary endpoint analysis was performed on the
intent-to-treat population (all randomized patients). In the
initial prospectively planned, primary efficacy analysis,
interactions between treatment and the covariates of
race, disease class (V or other) and region were assessed
at the 0.1 level. If the P-value of the interaction term was
40.10, the interaction for that term was explored. Odds
ratios (ORs) were calculated using logistic regression
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group and the covariates defined above.
At randomization, patients were stratified by race
into three groups—Asian, White and a combined Black
and Other group. The combined Black and Other group
was split, and analysis of the effects of the variable Black
(self-reported racial group) on response to treatment
was performed post hoc using the chi-square test. The
additional post hoc analysis of the variable Black and
subsequent terminology reported herein differs from that
documented previously [18]. To assess the effects of
ethnicity (Hispanic vs non-Hispanic), the primary efficacy
endpoint data were analysed post hoc using logistic
regression models that included the covariates of
treatment and disease class.
Baseline disease characteristics and secondary efficacy
variables by race and region were summarized post hoc
using descriptive statistics. No formal statistical tests
were performed. To identify potential risk factors for
death, serious AEs (SAEs) and infection, post hoc
analyses using logistic regression were performed.
Factors included demographic variables and baseline
disease characteristics. Analyses were performed using
SAS software, version 9.1 (SAS Institute, Cary, NC, USA).
Results
Demographics
A total of 370 patients were randomly assigned to treat-
ment with MMF or IVC. Of these, 147 (39.7%) patients
reported their race as White, 123 (33.2%) as Asian
(mostly in China), 46 (12.4%) as Black and 54 (14.6%)
as Other. Of the 54 patients classified as Other, 28
(7.6%; all from Latin America) reported their race as
Mexican–Mestizo, 9 (2.4%) as mixed race, 3 (0.8%) as
Hispanic and 14 (3.8%) were unclassifiable. Across all
racial groups, 131 (35.4%) patients, mostly from Latin
America, stated their ethnicity as Hispanic. Demographic
and baseline characteristics by race and region are
presented in Table 1 and Supplementary Table 1,
respectively.
Baseline disease characteristics byrace andregion
At baseline, age at onset of SLE was comparable across
racial and treatment groups. Asian patients had the
shortest median time since the diagnosis of SLE when
assessed by race (Table 1) and region (Supplementary
Table 1).
Compared with their counterparts assigned to IVC,
patients in the Asian and Other race groups who were
assigned to MMF appeared to have worse renal function
with respect to mean glomerular filtration rate (GFR) and
were also more likely to have an estimated GFR of
<30ml/min/1.73m
2 (Table 1). However, within racial
groups, no statistically significant treatment differences
in the proportion of patients with estimated GFR
<30ml/min/1.73m
2 were observed (Asian: 95% CI  1.2,
17.0; P¼0.093; White: 95% CI  7.7, 12.3; P¼0.658;
Black: 95% CI  14.5, 4.6; P¼0.249; Other: 95% CI
 6.4, 30.0; P¼0.170). Similarly, patients receiving MMF
had a lower mean GFR, notably those from Asia and, to
a lesser extent, those from Latin America (Supplementary
Table 1). Asian and Other race groups had slightly higher
mean P/Cr ratios than White or Black groups (Table 1).
However, the regional groups appeared similar for this
parameter (Supplementary Table 1). USA and Canada
had the highest percentage of Class V patients with LN,
whereas the Rest of World had the lowest percentage of
Class V patients (Supplementary Table 1). A slightly higher
percentage of patients in the Black group had Class V LN
in the MMF and IVC groups compared with those in
the other racial groups. A slightly higher percentage of
patients in the Other group receiving MMF compared
with IVC had combined Class III/III þ V disease and
renal scarring on biopsy (Table 1). A higher proportion of
patients in the Black group (76%) and patients from
USA/Canada (76%) and Rest of World (82%) had a
medical history of hypertension at baseline compared
with other races (46–65%) and regions (46–50%). Similar
proportions of patients were taking an angiotensin-
converting enzyme inhibitor (ACEI) or angiotensin II recep-
tor blocker (ARB) in the MMF and IVC groups: 73.9% in
both groups. Overall, there were no striking differences
between racial or regional groups for either treatment
group in any other baseline parameters (Table 1 and
Supplementary Table 1).
More patients withdrew from the MMF than IVC group
in the Asian [19/62 (30.6%) vs 7/61 (11.5%); P¼0.009;
95% CI 5.1, 33.1] and White [11/75 (14.7%) vs 6/72
(8.3%); P¼0.230; 95% CI  3.8, 16.6] groups. In contrast,
there were fewer withdrawals from the MMF than IVC
group among patients in the Black [3/26 (11.5%) vs
11/20 (55.0%); P¼0.002; 95% CI  68.5,  18.5] and
Other race group [2/22 (9.1%) vs 5/32 (15.6%);
P¼0.482; 95% CI  23.9, 10.9]. When withdrawal rates
were examined by region, more patients in USA/Canada
withdrew vs those receiving IVC in other regions.
Conversely, a higher number of patients from Asia
withdrew from the MMF group compared with those
from other regions.
Drugexposure
Exposure to treatment was assessed in the safety
population. The median dosage was calculated for
170 patients in the MMF group as 2.6g/day [18]. The
races were well balanced in terms of the average daily
dose of MMF received: each group received between
2.4 and 2.8g/day. In general, most patients [168/184
(91.3%)] tolerated MMF of 2.5–3.0g/day in all regional
groups. The duration of MMF exposure was slightly
lower in the Asian group (mean exposure of 146.2 vs
159.2–165.8 days for other racial groups). The median
MMF dose was also lower among patients from
the Asian group (2.4g) compared with other groups
(2.6–2.8g). Due to flat dosing in the MMF arm, MMF expo-
sure by body weight was examined. At Weeks 20–24,
median daily MMF dose was similar across the racial
groups: 0.042g/kg in White, 0.044g/kg in Black,
130 www.rheumatology.oxfordjournals.org
David Isenberg et al.T
A
B
L
E
1
B
a
s
e
l
i
n
e
d
i
s
e
a
s
e
c
h
a
r
a
c
t
e
r
i
s
t
i
c
s
o
f
p
a
t
i
e
n
t
s
,
b
y
r
a
c
e
a
n
d
t
r
e
a
t
m
e
n
t
g
r
o
u
p
R
a
c
e
A
s
i
a
n
W
h
i
t
e
O
t
h
e
r
B
l
a
c
k
C
h
a
r
a
c
t
e
r
i
s
t
i
c
M
M
F
(
n
¼
6
2
)
I
V
C
(
n
¼
6
1
)
M
M
F
(
n
¼
7
5
)
I
V
C
(
n
¼
7
2
)
M
M
F
(
n
¼
2
2
)
I
V
C
(
n
¼
3
2
)
M
M
F
(
n
¼
2
6
)
I
V
C
(
n
¼
2
0
)
A
g
e
a
t
d
i
a
g
n
o
s
i
s
o
f
S
L
E
,
y
e
a
r
s
2
7
.
9
(
8
.
6
4
)
2
6
.
9
(
9
.
3
1
)
2
7
.
2
(
1
1
.
0
1
)
2
6
.
6
(
1
0
.
5
8
)
2
7
.
2
(
9
.
5
8
)
2
5
.
8
(
8
.
7
4
)
2
7
.
5
(
1
1
.
9
2
)
2
8
.
6
(
8
.
7
0
)
T
i
m
e
s
i
n
c
e
d
i
a
g
n
o
s
i
s
o
f
S
L
E
,
y
e
a
r
s
1
.
0
(
1
–
2
3
)
1
.
0
(
1
–
1
1
)
3
.
0
(
1
–
2
4
)
4
.
0
(
1
–
2
7
)
6
.
0
(
1
–
2
5
)
3
.
0
(
1
–
3
0
)
2
.
0
(
1
–
3
8
)
4
.
0
(
1
–
1
2
)
A
g
e
a
t
d
i
a
g
n
o
s
i
s
o
f
L
N
,
y
e
a
r
s
2
8
.
8
(
8
.
5
3
)
2
7
.
3
(
9
.
4
4
)
3
0
.
5
(
1
1
.
5
5
)
2
9
.
4
(
1
0
.
8
0
)
3
2
.
1
(
1
0
.
8
6
)
2
8
.
8
(
1
0
.
6
9
)
3
1
.
3
(
1
4
.
1
9
)
3
0
.
9
(
9
.
3
1
)
T
i
m
e
s
i
n
c
e
d
i
a
g
n
o
s
i
s
o
f
L
N
,
y
e
a
r
s
1
.
0
(
1
–
2
1
)
1
.
0
(
1
–
1
1
)
1
.
0
(
1
–
1
9
)
1
.
0
(
1
–
2
3
)
1
.
5
(
1
–
1
5
)
1
.
0
(
1
–
2
1
)
1
.
0
(
1
–
8
)
1
.
0
(
1
–
1
2
)
R
e
n
a
l
b
i
o
p
s
y
c
l
a
s
s
C
l
a
s
s
I
I
I
5
(
8
.
1
)
4
(
6
.
6
)
7
(
9
.
3
)
6
(
8
.
3
)
4
(
1
8
.
2
)
2
(
6
.
3
)
5
(
1
9
.
2
)
2
(
1
0
.
0
)
C
l
a
s
s
I
I
I
/
I
I
I
þ
V
7
(
1
1
.
3
)
9
(
1
4
.
8
)
1
2
(
1
6
.
0
)
1
0
(
1
3
.
9
)
7
(
3
1
.
8
)
3
(
9
.
4
)
6
(
2
3
.
1
)
4
(
2
0
.
0
)
C
l
a
s
s
I
V
/
I
V
þ
V
4
7
(
7
5
.
8
)
4
5
(
7
3
.
8
)
5
3
(
7
0
.
7
)
5
3
(
7
3
.
6
)
1
2
(
5
4
.
5
)
2
1
(
6
5
.
6
)
1
2
(
4
6
.
2
)
9
(
4
5
.
0
)
C
l
a
s
s
I
V
o
n
l
y
4
4
(
7
1
.
0
)
4
1
(
6
7
.
2
)
5
0
(
6
6
.
7
)
4
8
(
6
6
.
7
)
1
0
(
4
5
.
5
)
1
5
(
4
6
.
9
)
1
0
(
3
8
.
5
)
7
(
3
5
.
0
)
C
l
a
s
s
V
o
n
l
y
8
(
1
2
.
9
)
7
(
1
1
.
5
)
1
0
(
1
3
.
3
)
9
(
1
2
.
5
)
3
(
1
3
.
6
)
8
(
2
5
.
0
)
8
(
3
0
.
8
)
7
(
3
5
.
0
)
S
c
a
r
r
i
n
g
o
n
r
e
n
a
l
b
i
o
p
s
y
1
3
(
2
1
.
0
)
1
4
(
2
3
.
0
)
3
0
(
4
0
.
0
)
2
4
(
3
3
.
3
)
a
1
0
(
4
5
.
5
)
1
0
(
3
1
.
3
)
1
3
(
5
0
.
0
)
8
(
4
0
.
0
)
H
y
p
e
r
t
e
n
s
i
o
n
3
3
(
5
3
.
2
)
2
4
(
3
9
.
3
)
3
6
(
4
8
.
0
)
3
9
(
5
4
.
2
)
1
7
(
7
7
.
3
)
1
8
(
5
6
.
2
5
)
1
9
(
7
3
.
1
)
1
6
(
8
0
.
0
)
U
r
i
n
e
P
/
C
r
4
.
7
(
5
.
6
2
)
b
4
.
1
(
2
.
7
5
)
b
3
.
7
(
3
.
2
1
)
c
3
.
8
(
3
.
3
2
)
d
4
.
3
(
3
.
5
5
)
5
.
0
(
3
.
7
8
)
e
3
.
8
(
2
.
8
5
)
3
.
8
(
2
.
8
5
)
f
E
s
t
i
m
a
t
e
d
G
F
R
,
m
l
/
m
i
n
/
1
.
7
3
m
2
8
6
.
4
(
4
2
.
5
8
)
1
0
3
.
4
(
4
7
.
6
8
)
8
3
.
1
(
4
4
.
8
2
)
8
1
.
7
(
3
8
.
1
0
)
6
6
.
0
(
3
4
.
8
8
)
9
1
.
9
(
4
3
.
0
5
)
1
0
3
.
8
(
4
4
.
4
6
)
9
7
.
1
(
5
5
.
9
9
)
G
F
R
<
3
0
m
L
/
m
i
n
/
1
.
7
3
m
2
7
.
0
(
1
1
.
3
)
2
.
0
(
3
.
4
)
9
.
0
(
1
2
.
0
)
7
.
0
(
9
.
7
)
4
.
0
(
1
8
.
1
)
2
.
0
(
2
.
3
)
0
1
(
5
.
0
)
S
e
r
u
m
a
l
b
u
m
i
n
c
o
n
c
e
n
t
r
a
t
i
o
n
,
g
/
l
3
1
.
6
(
6
.
9
6
)
g
2
9
.
3
(
6
.
6
6
)
3
0
.
6
(
7
.
2
1
)
2
9
.
6
(
7
.
1
3
)
2
8
.
7
(
5
.
7
0
)
2
7
.
5
(
7
.
1
8
)
2
9
.
0
(
6
.
5
4
)
2
5
.
1
5
(
6
.
2
0
)
h
P
a
t
i
e
n
t
s
w
i
t
h
n
e
g
a
t
i
v
e
a
n
t
i
-
d
s
D
N
A
a
n
t
i
b
o
d
y
b
i
n
d
i
n
g
l
e
v
e
l
a
t
b
a
s
e
l
i
n
e
1
6
(
2
5
.
8
)
1
1
(
1
8
.
0
)
6
(
8
.
3
)
8
(
1
1
.
1
)
0
(
0
)
2
(
6
.
2
5
)
1
0
(
3
8
.
5
)
2
(
1
0
.
0
)
G
e
o
m
e
t
r
i
c
a
n
t
i
-
d
s
D
N
A
a
n
t
i
b
o
d
y
b
i
n
d
i
n
g
l
e
v
e
l
7
7
.
2
(
3
.
6
4
)
9
9
.
5
(
5
.
8
4
)
1
0
9
.
2
(
2
.
2
1
)
1
0
6
.
9
(
2
.
5
2
)
i
9
8
.
0
(
1
.
9
8
)
j
1
1
6
.
0
(
2
.
2
8
)
e
7
7
.
8
(
1
.
6
6
)
6
3
.
2
(
1
.
6
5
)
f
P
a
t
i
e
n
t
s
w
i
t
h
l
o
w
(
<
9
0
m
g
/
d
l
)
C
3
c
o
n
c
e
n
t
r
a
t
i
o
n
s
a
t
b
a
s
e
l
i
n
e
4
7
(
7
5
.
8
)
4
8
(
7
8
.
6
)
5
4
(
7
2
.
0
)
5
1
(
7
0
.
8
)
1
3
(
5
9
.
1
)
2
5
(
7
8
.
1
)
1
1
(
4
2
.
3
)
1
5
(
7
5
.
0
)
G
e
o
m
e
t
r
i
c
C
3
c
o
n
c
e
n
t
r
a
t
i
o
n
,
m
g
/
d
l
6
3
.
8
(
1
.
5
7
)
e
5
5
.
9
(
1
.
6
9
)
6
7
.
7
(
1
.
4
4
)
6
2
.
8
(
1
.
5
9
)
k
6
9
.
1
(
1
.
5
8
)
j
5
8
.
2
(
1
.
5
8
)
7
7
.
8
1
(
1
.
6
6
)
6
3
.
2
2
(
1
.
6
5
)
f
P
a
t
i
e
n
t
s
w
i
t
h
l
o
w
(
<
1
6
m
g
/
d
l
)
C
4
c
o
n
c
e
n
t
r
a
t
i
o
n
s
a
t
b
a
s
e
l
i
n
e
3
0
(
4
8
.
4
)
4
0
(
6
5
.
6
)
4
8
(
6
4
.
0
)
4
9
(
6
8
.
1
)
1
1
(
5
0
.
0
)
2
3
(
7
1
.
8
)
1
5
(
5
7
.
7
)
1
3
(
6
5
.
0
)
G
e
o
m
e
t
r
i
c
C
4
c
o
n
c
e
n
t
r
a
t
i
o
n
,
m
g
/
d
l
1
3
.
2
(
2
.
0
5
)
e
1
0
.
4
(
2
.
0
1
)
9
.
7
(
2
.
2
0
)
9
.
6
(
2
.
0
5
)
k
1
1
.
9
(
2
.
0
1
)
j
8
.
3
(
2
.
1
3
)
e
1
2
.
8
6
(
2
.
3
2
)
1
0
.
4
7
(
2
.
3
5
)
S
E
L
E
N
A
–
S
L
E
D
A
I
t
o
t
a
l
s
c
o
r
e
1
4
.
9
(
5
.
4
7
)
1
5
.
7
(
6
.
2
8
)
1
5
.
3
(
6
.
9
1
)
1
6
.
3
(
7
.
2
8
)
1
4
.
4
(
8
.
7
2
)
1
6
.
1
(
7
.
7
1
)
1
3
.
1
(
6
.
6
7
)
1
4
.
2
(
5
.
8
3
)
V
a
l
u
e
s
a
r
e
g
i
v
e
n
a
s
m
e
a
n
(
S
.
D
.
)
o
r
m
e
d
i
a
n
(
r
a
n
g
e
)
f
o
r
c
o
n
t
i
n
u
o
u
s
v
a
r
i
a
b
l
e
s
,
a
n
d
n
(
%
)
f
o
r
c
a
t
e
g
o
r
i
c
a
l
v
a
l
u
e
s
.
a
D
a
t
a
m
i
s
s
i
n
g
f
o
r
o
n
e
p
a
t
i
e
n
t
;
b
n
¼
6
0
;
c
n
¼
7
2
;
d
n
¼
7
1
;
e
n
¼
3
1
;
f
n
¼
1
9
;
g
n
¼
5
9
;
h
n
¼
1
8
;
i
n
¼
6
8
;
j
n
¼
2
1
;
k
n
¼
6
9
.
www.rheumatology.oxfordjournals.org 131
Race/ethnicity and lupus nephritis treatment0.049g/kg in Asian and 0.05g/kg in Other. At Weeks
20–24, patients in USA/Canada had a lower median
daily MMF dose (0.036g/kg) compared with other regions
where median daily dose ranged from 0.043 to 0.051g/kg.
The results of the population pharmacokinetic analysis
of patients receiving MMF suggested that race did not
influence the pharmacokinetics of this drug.
The median total dosage per infusion of IVC was
0.75g/m
2 [18]. The median total dosage per infusion
was slightly higher in the Other and Black racial groups
(0.840 and 0.875g/m
2, respectively) compared with the
Asian and White groups (0.785 and 0.750g/m
2, respec-
tively) [18]. However, the mean duration and number of
doses of IVC were less for patients in the Black group
(138 days and 4.83 infusions, respectively) compared
with 160.5–167.04 days and 5.65–5.80 infusions for
other groups. Only 50.0% of the patients in the Black
group received treatment for 24 weeks compared with
the entire IVC safety population (71.7%). There were
observed differences in exposure by region: patients
from USA/Canada who were receiving IVC had fewer
infusions compared with patients from other regions.
Efficacy
Primary efficacy endpoint. The primary efficacy endpoint
was achieved in 104 (56.2%) patients receiving MMF
compared with 98 (53.0%) patients receiving IVC
(P¼0.58; OR 1.2; 95% CI 0.8, 1.8) [18]. As previously
reported, there were important pre-specified interactions
between treatment group and race (P¼0.047) and
between treatment group and geographical region
(P¼0.069) [18]. The number of patients achieving the
primary efficacy endpoint was not significantly different
between the treatment groups, irrespective of adjustment
for covariates. Although there were racial and regional
differences in the incidence of LN classes between
the groups (Table 1 and Supplementary Table 1),
this did not appear to contribute to differences in
outcome as Class V patients showed a similar response
to non-Class V patients. The pre-specified intera-
ction between treatment group and LN class was not
significant (P>0.10). Use of non-immunosuppressive
co-medications and blood pressure control had no
impact on response. Response rates with MMF and IVC
were similar for Asian (53.2 and 63.9%, respectively;
P¼0.24; OR 0.6; 95% CI 0.3, 1.3) and White (56.0 and
54.2%, respectively; P¼0.83; OR 1.1; 95% CI 0.6, 2.1)
groups. However, more patients in the combined Other
and Black group responded to MMF (60.4 and 38.5%;
P¼0.03; OR 2.4; 95% CI 1.1, 5.4) compared with IVC.
Among patients in the Black group, 53.9% responded to
MMF and 40.0% to IVC (OR 1.75; 95% CI 0.54, 5.70;
P¼0.39) (Fig. 1A). Response rates among Hispanic
patients also differed: 60.9% for MMF vs 38.8% for IVC
(OR 2.5; 95% CI 1.2, 5.1; P¼0.011). Consistent with these
findings, patients from Latin America were more likely to
have responded to MMF than IVC (60.7 vs 32.0%;
P¼0.003; OR 3.4; 95% CI 1.5, 7.7) (Fig. 1B). There was
no significant difference in response rates between the
treatments in the remaining regions, and rates for MMF
were comparable across all regions (Fig. 1B). However,
the response rate for IVC was lower in Latin America
(32%) than in the other regions (47–68%).
Asian, Other and Black racial groups had greater
improvements with MMF than IVC in analyses of the
median change from baseline in urine P/Cr, whereas the
opposite was observed for patients in the White group
(Table 2). In Asia and Latin America, improvements in
P/Cr for MMF were greater than those for IVC (Table 3).
However, in USA/Canada, greater improvements were
observed for IVC compared with MMF.
There was no difference between the two treatment
groups with respect to median time to 50% reduction in
proteinuria (86 days for IVC vs 81 days for MMF). In all
racial groups, with the exception of the Black group,
the median time to a 50% reduction in 24-h urine protein
was shorter for MMF than IVC (Table 2), although these
findings were not statistically significant. Similarly, the
time to a 50% reduction in 24-h urine protein was shorter
for MMF than IVC across all regions except USA/Canada
(Table 3).
Secondary efficacy endpoints. Mean changes from base-
line to endpoint in the BILAG subscales and total SLEDAI
score (Table 2) did not differ between treatment groups or
between racial groups. However, when comparing
regions, patients from USA/Canada and the Rest of
World showed greater improvements in total SLEDAI
score compared with other regions, regardless of treat-
ment group (Table 3).
Additional analyses. There appeared to be no significant
differences in the change between the groups in C3
and C4 or anti-dsDNA levels at endpoint compared with
baseline in racial (Table 2) and regional (Table 3) groups.
Any differences observed were also apparent at baseline;
therefore, any change in a measured parameter was
relative to the pattern observed at baseline and deemed
to be of no clinical relevance. In addition, duration of
disease, baseline anti-dsDNA antibody levels and mean
BMI did not appear to influence response to treatment.
Safety
Overall, the incidence of AEs was comparable between
the two treatment groups; the majority of patients in all
racial groups reported at least one AE (Table 4).
In the MMF group, fewer Asian patients reported
diarrhoea than all other patients. Anaemia, a known
adverse effect of MMF, was reported least by the White
group (Table 4). More patients in the Rest of World
category reported anaemia than in any other region,
irrespective of treatment. Alopecia was more commonly
reported with IVC than MMF.
A higher incidence of hypertension expressed as an AE
was reported in patients from the Other group compared
with the Asian, White and Black groups (Table 4). Similar
proportions of patients in the MMF and IVC Other group
reported this AE (22.7 vs 29.0%). Fewer patients in the
Asian racial (61%) and regional (62%) groups were
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compared with those from other racial (81–89%) and
regional (81–85%) groups. Infection was reported less
frequently among Asian patients (Fig. 2). Sites from Asia
also reported the lowest rate of infections.
More patients in the White, Asian and combined Other
and Black groups who received MMF withdrew due to
AEs (8.1, 22.6 and 9.1%, respectively) compared with
the IVC group (2.8, 5.0 and 3.2%, respectively). In
contrast, more patients in the Black group receiving
IVC withdrew due to AEs (38.9%) compared with those
receiving MMF (7.7%).
Among patients from Asia, those receiving IVC had a
lower rate of withdrawal due to AEs (5.1%) than MMF
(22.8%). Differences in withdrawal due to AEs between
the treatment groups did not appear to be influenced by
variations between the groups with respect to BMI or
overexposure to the drug (dose per body weight).
FIG.1 Percentage of patients achieving the primary efficacy endpoint, by race and treatment group (A), where Black is a
subset of the Other racial group; and percentage of patients achieving the primary efficacy endpoint, by region and
treatment group (B) (intent-to-treat populations).
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Race/ethnicity and lupus nephritis treatmentTABLE 4 Most commonly reported treatment-emergent AEs, by race and treatment group (safety population)
Race
Asian White Other Black
Patients who experienced
at least one AE
MMF
(n¼62)
IVC
(n¼60)
MMF
(n¼74)
IVC
(n¼71)
MMF
(n¼22)
IVC
(n¼31)
MMF
(n¼26)
IVC
(n¼18)
All AEs 59 (95.2) 54 (90.0) 72 (97.3) 69 (97.2) 46 (95.8) 48 (98.0) 25 (96.2) 18 (100)
Diarrhoea 10 (16.1) 6 (10) 27 (36.5) 9 (12.7) 6 (27.3) 5 (16.1) 9 (34.6) 3 (16.7)
Nausea and vomiting 13 (21.0) 32 (53.3) 20 (27.0) 40 (56.3) 3 (13.6) 17 (54.8) 6 (23.1) 9 (50.0)
Headache 6 (9.7) 3 (5.0) 18 (24.3) 24 (33.8) 1 (4.5) 14 (45.2) 6 (23.1) 9 (50.0)
Joint-related signs and symptoms
(arthralgia)
6 (9.7) 8 (13.3) 18 (24.3) 24 (33.8) 0 (0) 8 (25.8) 7 (26.9) 3 (16.7)
Gastrointestinal and abdominal pain 5 (8.1) 4 (6.7) 19 (25.7) 11 (15.5) 4 (18.2) 9 (29.0) 6 (23.1) 6 (33.3)
Musculoskeletal and connective tissue
signs and symptoms (back pain)
4 (6.5) 3 (5.0) 15 (20.3) 14 (19.7) 4 (18.2) 6 (19.4) 8 (30.8) 5 (27.8)
Oedema 13 (21.0) 12 (20.0) 18 (24.3) 22 (31.0) 4 (18.2) 10 (32.3) 7 (26.9) 7 (38.9)
Upper respiratory tract infections 23 (37.1) 24 (40) 3 (4.1) 10 (14.1) 6 (27.3) 10 (32.3) 6 (23.1) 7 (38.9)
Alopecia 7 (11.3) 17 (28.3) 10 (13.5) 31 (43.7) 4 (18.2) 9 (29.0) 2 (7.7) 4 (22.2)
Coughing 12 (19.4) 4 (6.7) 10 (13.5) 10 (14.1) 4 (18.2) 6 (19.4) 6 (23.1) 6 (33.3)
Hypertension 6 (9.7) 1 (1.7) 11 (14.9) 12 (16.9) 5 (22.7) 9 (29.0) 4 (15.4) 3 (16.7)
Anaemia 19 (16.1) 0 (0) 6 (8.1) 4 (5.6) 3 (13.6) 8 (25.8) 4 (15.4) 1 (5.6)
Rashes, eruptions and exanthema 6 (9.7) 5 (8.3) 8 (10.8) 12 (16.9) 0 (0) 3 (9.7) 5 (19.2) 6 (33.3)
Asthenic conditions (fatigue) 7 (11.3) 4 (6.7) 13 (17.6) 18 (25.4) 0 (0) 4 (12.9) 6 (23.1) 5 (27.8)
Febrile disorders 5 (8.1) 15 (25.0) 7 (9.5) 12 (16.9) 0 (0) 2 (6.5) 0 (0) 1 (5.6)
Muscle-related signs and symptoms
(muscle spasm)
3 (4.8) 1 (1.7) 9 (12.2) 10 (14.1) 1 (4.5) 5 (16.1) 6 (23.1) 3 (16.7)
Urinary tract infections 0 (0) 0 (0) 10 (13.5) 7 (9.9) 2 (9.1) 5 (16.1) 4 (15.4) 2 (11.1)
Leucopenias 5 (8.1) 8 (13.3) 2 (2.7) 17 (23.9) 4 (18.2) 12 (38.7) 1 (3.8) 5 (27.8)
Potassium imbalance (hypokalaemia) 0 (0) 0 (0) 2 (2.7) 2 (2.8) 2 (9.1) 3 (9.7) 6 (23.1) 1 (5.6)
Menstruation with decreased bleeding
(amenorrhoea)
0 (0) 1 (1.7) 0 (0) 2 (2.8) 0 (0) 5 (16.1) 1 (3.8) 2 (11.1)
All SAEs 21 (33.9) 17 (28.3) 18 (24.3) 16 (22.5) 5 (22.7) 5 (16.1) 7 (26.9) 3 (16.7)
All infections 39 (62.9) 29 (48.3) 54 (73.0) 54 (76.1) 33 (68.8) 28 (57.1) 21 (80.8) 10 (55.6)
Values are given as n (%).
FIG.2 Percentage of patients reporting AEs, by race and treatment group. Patients could experience more than one AE.
Any infection includes lower and upper respiratory tract plus any other infections. Any AE includes infections plus other
AEs. Groups of AEs are not exclusive. Values on the y-axis represent a cumulative percentage; for example, the value for
any AE represents the total percentage of patients with lower and upper respiratory tract infection, any other infection
plus any other AE.
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David Isenberg et al.In the MMF group, there were two deaths in
Argentina (both due to septic shock), six deaths in China
(interstitial lung disease¼one, lung infection¼one,
pneumonia¼two, respiratory tract infection¼one and
unknown¼one) and one death in Malaysia (due to
septicaemia). In the IVC group, there were two deaths in
the USA (LN¼one and unknown¼one), two in China
(serious mixed infection¼one and cerebrovascular
accident¼one) and one death in the UK (due to subacute
endocarditis).
Post hoc analysis of treatment differences for deaths,
SAEs and infections did not show statistical significance
between MMF and IVC (4.9 vs 2.8%; P¼0.29; 27.7 vs
22.8%; P¼0.28; and 68.5 vs 61.7%; P¼0.17,
respectively). The analysis also revealed no significant
treatment-by-factor interactions for race, ethnicity,
region, body surface area or weight on adverse outcome
(deaths, SAEs or infectious AEs). Independent of treat-
ment, however, race and region were associated with
the incidence of infectious AEs (P¼0.0072 and 0.0095,
respectively) (Fig. 3).
Discussion
Observations suggest that the mechanisms of LN may
differ among racial and ethnic subsets; hence, the
effectiveness of therapeutic interventions may also vary.
For instance, Black and Hispanic patients have an
increased risk of aggressive disease [12, 13], and a
greater prevalence of renal failure has also been reported
among Black patients [25], with genetic rather than socio-
economic factors believed to be a more likely cause.
Previous trials have found MMF to be at least as
effective as IVC as induction treatment for LN; but ana-
lyses were limited to patients in single countries and the
trial sizes did not allow for comparisons between racial
groups [26–30]. ALMS, however, provides the most
extensive dataset to date that allows variations in
response to the two most commonly used treatments
for LN to be addressed directly.
The results from this global study suggest that race and
geographical region do influence response to therapy.
Possible reasons that may have contributed to this obser-
vation include differences between subgroups with
respect to disease characteristics at baseline, differences
in how subgroups metabolize the respective drugs,
variations in treatment tolerability and regional differences
in patient management/socio-economic factors. The
greater number of responders with MMF than IVC in the
Black and Latin American groups suggests a difference in
efficacy between the two drugs in these populations. This
difference in efficacy observed in Black and Latin
American groups is supported by the reduction in mean
IVC dose among patients in the Black group compared
with other racial groups.
Further, more patients in the Black group receiving IVC
were likely to withdraw prematurely from the study due to
AEs than other racial groups, resulting in differences in
exposure across racial groups. Variation in exposure to
either of the treatments was also seen across regional
groups; exposure to IVC was lower in the USA and
Canada than other regions because of differences in the
proportions of patients completing the full 24 weeks of
treatment (withdrawal rates were higher in USA/Canada).
Lower exposure was driven by fewer infusions due to
premature withdrawal rather than patients requiring a
reduced dose due to renal failure. Conversely, patients
in the Asian group demonstrated a reduced tolerability
to MMF, exhibiting a higher withdrawal rate due to AEs,
compared with other racial groups.
However, it is difficult to draw firm conclusions from
drug exposure according to patient weight, because
FIG.3Effects of race and region on the incidence of infectious AEs. The asterisk indicates P-value for factor, obtained
from a logistic regression analysis of all patients modelling infectious AEs with a main effect for factor.
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Race/ethnicity and lupus nephritis treatmentdosing of both drugs was frequently reduced due to AEs,
which confounds the apparent outcome in patients taking
lower doses. Despite differences in withdrawal due to AEs
in patients from Asia, there was no effect on overall effi-
cacy MMF and IVC compared with other regions. Indeed,
the overall efficacies of MMF and IVC were comparable,
but for certain racial and ethnic groups, MMF may offer
better efficacy and tolerability as induction treatment.
ALMS provides the most compelling data currently avail-
able that certain patient populations are less likely to
respond to IVC, supporting the anecdotal evidence from
clinical practice that the efficacy of IVC varies between
racial and ethnic groups.
Baseline disease characteristics did not appear to have
any noticeable predictive value for response to therapy.
There were differences in baseline factors observed
between racial/regional groups and within some racial
groups. More patients in the Black group and from USA/
Canada had Class V LN, and these patients were also
more likely to be hypertensive and taking immuno-
suppressive co-medications. However, there is no indica-
tion that these parameters had an impact on treatment
response. Overall, patients from Asia reported the
fewest infections, but those infections were more likely
to be severe, resulting in hospitalization or death.
Notably, these events were largely localized to one
region within Asia. Analysis of the potential impact of
possible predictor variables on adverse outcomes
did not explain the numerical differences between
treatment groups in the numbers of deaths, SAEs and
infections.
Firm conclusions cannot be drawn from this study as
a number of the assessments described here were
exploratory analyses performed on a post hoc basis
subsequent to the initial, prospectively planned, primary
efficacy analysis, and thus must be interpreted as such.
Furthermore, the trial was not designed to be powered to
detect an effect of a specific region, race or ethnicity; the
small numbers of patients in each subgroup do not allow
these findings to be generalized to the larger population
of patients with LN.
Also, due to the complex nature of the relationship
between race, ethnicity and geographical region, we
cannot distinguish between these factors in terms of
importance. Designations of race and ethnicity are often
arbitrary (and in this study, self-reported) and hetero-
geneous [31], and there can be notable differences in
clinical, prognostic and socio-economic features, educa-
tion and access to medical care within a geographical
region [32]. Further, these categories are not discrete,
and the overlap of races and ethnicities may have
masked differences in response among these groups. In
spite of the attempt to standardize the management of LN
across regions by strict trial monitoring, differences in
treatment response were observed in Latin America com-
pared with the other regions. Although the role of some
socio-economic factors can be reduced in a clinical study,
they cannot be removed entirely, and their differentiation
from genetic factors remains a challenge.
Other factors that were uncontrolled in this study may
have been a source of bias, such as regional differences in
prior immunosuppressive drug use. For example, patients
who had received previous IVC therapy might have been
less likely to respond to IVC in ALMS. As details on prior
therapy were not collected, it is not clear whether this
potential source of bias contributed, for example, to the
difference in IVC response seen across regions.
Another limitation may have been the 24-week induc-
tion period, which may have been too short to differentiate
between the treatments. The duration of this induction
phase was comparable with that of previous studies, how-
ever [15, 28, 30, 33, 34], and further data will be collected
during the ongoing maintenance phase.
In conclusion, exploratory findings from this large,
international study indicate that although MMF and IVC
are of similar efficacy, race, ethnicity and geographical
region may be important factors in response to treatment
among patients with LN. More patients from the Black and
Hispanic groups appeared to respond to MMF than IVC,
and more patients from the Asian group withdrew from
MMF than IVC treatment. However, due to the complex
nature of the relationship between race, ethnicity and
geographical region, we cannot distinguish between
these factors in terms of importance. Nonetheless,
the ALMS data provide some valuable insights regarding
the interaction of these factors.
Rheumatology key messages
. Racial, ethnic or regional variations may influence
the incidence, prevalence and prognosis of LN.
. MMF and IVC have similar efficacy as short-term
induction therapy; race, ethnicity and region may
affect response.
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